Overview

Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
A study in healthy volunteers of the next morning driving performance after middle-of-the-night dosing of 3.5 mg zolpidem tartrate sublingual tablet, a sleep aid. The next morning driving performance will be measured by taking a standardized driving test.
Phase:
Phase 1
Details
Lead Sponsor:
Transcept Pharmaceuticals
Treatments:
Hypnotics and Sedatives
Zolpidem
Zopiclone